As MR guided focused ultrasound (MRgFUS) treatments evolve to treat oncological diseases, the ability to accurately assess the efficacy of treatment is critical. Although there are several MR metrics proposed for assessing MRgFUS treatments, they have not been rigorously validated against gold standard histopathology treatment assessment. Current validation studies that register MR to histopathology do not comprehensively account for all deformations during histological processing. We present a rigorous MR to histopathology registration pipeline that estimates deformation at every step that can be used to accurately validate the efficacy of oncological MRgFUS treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords